Core Insights - Coya Therapeutics, Inc. is focused on developing therapies that modulate regulatory T cells to treat neurodegenerative, autoimmune, and metabolic diseases [1] - The consensus price target for Coya has remained stable at $17, with a more optimistic target of $18 from analyst Raghuram Selvaraju [2][6] - A recent 10.7% increase in Coya's share price indicates investor optimism, although earnings estimate revisions have not shown sustained improvement [3][6] - Future clinical trial results and regulatory approvals are critical for the company's stock performance and future price targets [4][6] - Advancements in Coya's product pipeline or strategic partnerships could influence analysts' perspectives on the company [5]